Get access

Chemerin and Vaspin: Possible Targets to Treat Obesity?

Authors

  • Stephan Schultz,

    1. Institute of Biochemistry; Faculty of Biosciences, Pharmacy and Psychology, Universität Leipzig, Brüderstraße 34, 04103 Leipzig (Germany)
    Search for more papers by this author
  • Prof. Dr. Annette G. Beck-Sickinger

    Corresponding author
    1. Institute of Biochemistry; Faculty of Biosciences, Pharmacy and Psychology, Universität Leipzig, Brüderstraße 34, 04103 Leipzig (Germany)
    • Institute of Biochemistry; Faculty of Biosciences, Pharmacy and Psychology, Universität Leipzig, Brüderstraße 34, 04103 Leipzig (Germany)
    Search for more papers by this author

Abstract

Obesity is one of the main human epidemics today. The increase in fat accumulation, which is associated with obesity, may significantly change the expression of several bioactive molecules known as adipokines. These adipokines interact not only with adipose tissue, but also with metabolically relevant organs such as liver and muscle. Understanding the molecular basics of potential novel targets might help to improve the therapeutic treatment of people who suffer from obesity. Herein we summarize the state of the art of two novel adipokines and their impaired or protective action in obesity: chemerin and vaspin. Their expression patterns, signal transduction activity, and resulting functions within the human body are introduced. We also discuss various possibilities to target these adipokines, which may represent promising new targets for the treatment of obesity by small and synthetic compounds.

Get access to the full text of this article

Ancillary